Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the INmune Bio Second Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being ...

Explore INmune Bio's Fair Values from the Community and select yours. Even when a business is losing money, it's possible for shareholders to make money if they buy a good busines ...

Thank you, operator, and good afternoon, everyone. We thank you for joining us for the call for INmune Bio's second quarter 2025 financial results. Presenting on today's call are David Moss, ...

Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ...

Explore INmune Bio's Q2 2025 earnings call: new CEO, strategic shifts, XPro's Alzheimer's pause, CORDStrom advancements, and a focus on partnerships.

The latest update is out from Inmune Bio ( (INMB) ).

XPro failed to meet primary endpoints in its Phase 2 Alzheimer’s trial, but showed some positive signals in a biomarker-enriched subgroup. Cash and cash equivalents increased to $33.4 million, ...

Shares of INmune Bio climbed after the biotech company said its trial for treatment of a certain prostate cancer met its targets. The stock was up 11%, to $2.83, but is still down 65% over the ...

Investing.com -- INmune Bio Inc. (NASDAQ: INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both ...

INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be ...

BOCA RATON - INmune Bio Inc. (NASDAQ:INMB), a $76 million market cap biotechnology company whose stock has surged nearly 28% in the past week, will release additional analyses from its Phase 2 ...

--INmune Bio Inc. announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be published on ...